Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M211,143Revenue (TTM) $M52,759Net Margin (%)17.5Altman Z-Score3.6
Enterprise Value $M233,519EPS (TTM) $1.4Operating Margin %27.5Piotroski F-Score5
P/E(ttm)22.9Beneish M-Score-2.9Pre-tax Margin (%)24.0Higher ROA y-yN
Price/Book11.210-y EBITDA Growth Rate %2.2Quick Ratio0.8Cash flow > EarningsY
Price/Sales4.15-y EBITDA Growth Rate %1.2Current Ratio1.1Lower Leverage y-yY
Price/Free Cash Flow18.7y-y EBITDA Growth Rate %1.3ROA % (ttm)12.4Higher Current Ratio y-yN
Dividend Yield %3.3PEG19.9ROE % (ttm)48.2Less Shares Outstanding y-yY
Payout Ratio %77.0Shares Outstanding M6,818ROIC % (ttm)28.2Gross Margin Increase y-yN

Gurus Latest Trades with RHHBY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RHHBYKen Fisher 2016-06-30 Add0.01%$30.26 - $33.68
($31.82)
$ 30.97-3%Add 1.58%15,142,209
RHHBYKen Fisher 2016-03-31 Add0.02%$30.09 - $34.47
($31.91)
$ 30.97-3%Add 1.88%14,906,191
RHHBYKen Fisher 2015-12-31 Add0.01%$32.55 - $35.08
($33.69)
$ 30.97-8%Add 0.63%14,630,453
RHHBYKen Fisher 2015-09-30 Add0.02%$31.65 - $36.87
($34.69)
$ 30.97-11%Add 2.30%14,538,602
RHHBYKen Fisher 2015-06-30 Add0.8%$34.38 - $38.46
($36.09)
$ 30.97-14%Add 409.71%14,211,412
RHHBYKen Fisher 2015-03-31 Reduce$32.1 - $36.505
($34.06)
$ 30.97-9%Reduce -1.24%2,788,126
RHHBYKen Fisher 2014-12-31 Add0.07%$34.16 - $37.92
($36.33)
$ 30.97-15%Add 49.26%2,823,025
RHHBYKen Fisher 2014-06-30 Reduce-0.07%$35.42 - $38.07
($36.82)
$ 30.97-16%Reduce -49.71%1,813,443
RHHBYKen Fisher 2014-03-31 Add0.07%$18.14 - $38.17
($29.75)
$ 30.974%Add 99.00%1,803,070
RHHBYKen Fisher 2013-12-31 Reduce$31.96 - $35.24
($34.15)
$ 30.97-9%Reduce -0.26%1,812,112
RHHBYKen Fisher 2013-09-30 Add$30.66 - $33.77
($31.86)
$ 30.97-3%Add 0.28%1,816,868
RHHBYTweedy Browne 2013-06-30 Sold Out $28.92 - $32.98
($30.92)
$ 30.970%Sold Out0
RHHBYKen Fisher 2013-06-30 Add$28.92 - $32.98
($30.92)
$ 30.970%Add 0.90%1,811,804
RHHBYKen Fisher 2013-03-31 Add0.12%$25.62 - $29.3
($27.78)
$ 30.9711%Add 634.57%1,795,722
RHHBYTweedy Browne 2012-12-31 Reduce$23.08 - $25.68
($24.54)
$ 30.9726%Reduce -3.04%120,548
RHHBYKen Fisher 2012-12-31 Reduce$23.08 - $25.68
($24.54)
$ 30.9726%Reduce -14.81%244,460
RHHBYTweedy Browne 2012-09-30 Reduce-0.03%$20.99 - $24.07
($22.5)
$ 30.9738%Reduce -24.31%124,328
RHHBYKen Fisher 2012-09-30 Reduce$20.99 - $24.07
($22.5)
$ 30.9738%Reduce -7.27%286,946
RHHBYVanguard Health Care Fund 2012-06-30 Add2.96%$19.43 - $23.14
($21.18)
$ 30.9746%Add 543.36%8,547,954
RHHBYKen Fisher 2012-06-30 Reduce-0.01%$19.43 - $23.14
($21.18)
$ 30.9746%Reduce -24.26%309,426
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RHHBY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


RHHBY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about RHHBY:

    News about RHHBY:

    Articles On GuruFocus.com
    Mairs and Power Buys Walt Disney, Exits Baxalta Sep 27 2016 
    Is Bristol-Myers Squibb Presenting an Opportunity? Sep 08 2016 
    Can Novartis Tide Over the Alcon Crisis? Aug 26 2016 
    Innovative Diagnostic and Therapeutic Products Seen at Roche Aug 22 2016 
    Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
    Roche Holdings Definitely Not a Lumbering Giant Jul 11 2016 
    Invesco Adds to Holdings in Investment, Financial Services Companies Jul 01 2016 
    Bearish Sentiment in Becton Dickinson's Stock Apr 27 2016 
    Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
    Invesco European Growth Fund Adds to More Than 40 Existing Stakes Apr 04 2016 

    More From Other Websites
    Regeneron Pharmaceuticals Falls As Combo Therapy Worse Than Eylea Alone Sep 30 2016
    3:10 am Roche Hldg receives FDA approval of a label extension of the cobas EGFR Mutation Test v2 Sep 29 2016
    Harmony® Prenatal Test for assessment of Down syndrome and other chromosomal disorders receives CE... Sep 29 2016
    FDA Grants Roche Label Extension for the cobas® EGFR Mutation Test v2 for use with Plasma as a... Sep 29 2016
    Looking Abroad for Quality Bargains Sep 28 2016
    Regeneron-Sanofi Could Beat Pfizer, Roche, AstraZeneca On Eczema Sep 26 2016
    Unexpected Twist: Pfizer Scraps Breakup Following Dead Allergen Merger Sep 26 2016
    Roche receives 510(k) clearance from FDA for Treponema pallidum assay to aid clinicians in the... Sep 26 2016
    Roche launches low-cost PT/INR home monitoring app Sep 26 2016
    How Roche’s Valuation Compares to Its Peers Sep 20 2016
    Doubtful about Roche’s Bladder Cancer Treatment? Look at Studies Sep 16 2016
    Roche Sees Soaring Revenue from Its Bladder Cancer Treatment Sep 16 2016
    Roche’s Oncology Wheelhouse Stacked with Competitive Drugs Sep 16 2016
    Roche Ocrevus Positive in Phase III Multiple Sclerosis Trials Sep 15 2016
    Phase III Efficacy Results of Investigational Medicine OCREVUS™ (Ocrelizumab) Reinforced by... Sep 14 2016
    Phase III Efficacy Results of Investigational Medicine OCREVUS™ (Ocrelizumab) Reinforced by... Sep 14 2016
    Drug Pricing Power Transcends Politics Sep 09 2016
    2 Hot Biotech Stocks Trading at Bargain Prices Right Now Sep 08 2016
    What Are the Possible Threats to Revlimid? Sep 08 2016
    Agios Stock Soars As Partner Celgene Preps Drug Filing Sep 07 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)